Financhill
Buy
56

BNGO Quote, Financials, Valuation and Earnings

Last price:
$0.28
Seasonality move :
-1.07%
Day range:
$0.25 - $0.36
52-week range:
$0.19 - $2.16
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.40x
P/B ratio:
0.60x
Volume:
38.1M
Avg. volume:
5.6M
1-year change:
-84.74%
Market cap:
$29.4M
Revenue:
$36.1M
EPS (TTM):
-$4.48

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BNGO
Bionano Genomics
$6.3M -$0.14 -41.24% -95.03% --
AKYA
Akoya Biosciences
$21.5M -$0.16 -19.84% -26.15% $3.50
AZTA
Azenta
$149.6M $0.06 -3.09% 86.12% --
BRKR
Bruker
$962.9M $0.74 12.69% -47.58% $74.01
HBIO
Harvard Bioscience
$24.2M $0.05 -14.22% 150% $6.25
RVTY
Revvity
$728.8M $1.37 4.98% 115.21% $138.68
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BNGO
Bionano Genomics
$0.29 -- $29.4M -- $0.00 0% 0.40x
AKYA
Akoya Biosciences
$2.29 $3.50 $113.3M -- $0.00 0% 1.30x
AZTA
Azenta
$50.00 -- $2.3B -- $0.00 0% 4.06x
BRKR
Bruker
$58.62 $74.01 $8.9B 28.18x $0.05 0.34% 2.68x
HBIO
Harvard Bioscience
$2.11 $6.25 $92M -- $0.00 0% 0.93x
RVTY
Revvity
$111.61 $138.68 $13.6B 54.01x $0.07 0.25% 5.06x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BNGO
Bionano Genomics
23.43% 1.031 37.24% 0.86x
AKYA
Akoya Biosciences
84.77% -0.963 56.35% 1.74x
AZTA
Azenta
-- 0.926 -- 3.10x
BRKR
Bruker
55.97% 1.745 21.87% 0.65x
HBIO
Harvard Bioscience
36.69% 0.002 32.27% 0.76x
RVTY
Revvity
28.69% 0.427 20.43% 2.66x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BNGO
Bionano Genomics
-$8.4M -$22.6M -121.16% -158.95% -727.05% -$13.3M
AKYA
Akoya Biosciences
$11.7M -$7.4M -52.65% -157.22% -41.8% -$9.7M
AZTA
Azenta
$69.4M -$11M -7.49% -7.49% -6.48% $1.7M
BRKR
Bruker
$418.8M $78.4M 9.46% 19.61% 7.74% $5.8M
HBIO
Harvard Bioscience
$12.8M -$1.7M -13.35% -20.42% -16.55% -$2M
RVTY
Revvity
$384.8M $96.2M 2.2% 3.24% 18.24% $125.6M

Bionano Genomics vs. Competitors

  • Which has Higher Returns BNGO or AKYA?

    Akoya Biosciences has a net margin of -728.57% compared to Bionano Genomics's net margin of -55.99%. Bionano Genomics's return on equity of -158.95% beat Akoya Biosciences's return on equity of -157.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    BNGO
    Bionano Genomics
    -139.08% -$0.52 $63.8M
    AKYA
    Akoya Biosciences
    62.32% -$0.21 $89.5M
  • What do Analysts Say About BNGO or AKYA?

    Bionano Genomics has a consensus price target of --, signalling upside risk potential of 246.74%. On the other hand Akoya Biosciences has an analysts' consensus of $3.50 which suggests that it could grow by 53.17%. Given that Bionano Genomics has higher upside potential than Akoya Biosciences, analysts believe Bionano Genomics is more attractive than Akoya Biosciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNGO
    Bionano Genomics
    0 4 0
    AKYA
    Akoya Biosciences
    2 5 0
  • Is BNGO or AKYA More Risky?

    Bionano Genomics has a beta of 2.220, which suggesting that the stock is 121.987% more volatile than S&P 500. In comparison Akoya Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BNGO or AKYA?

    Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akoya Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics pays -- of its earnings as a dividend. Akoya Biosciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BNGO or AKYA?

    Bionano Genomics quarterly revenues are $6.1M, which are smaller than Akoya Biosciences quarterly revenues of $18.8M. Bionano Genomics's net income of -$44.2M is lower than Akoya Biosciences's net income of -$10.5M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Akoya Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.40x versus 1.30x for Akoya Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNGO
    Bionano Genomics
    0.40x -- $6.1M -$44.2M
    AKYA
    Akoya Biosciences
    1.30x -- $18.8M -$10.5M
  • Which has Higher Returns BNGO or AZTA?

    Azenta has a net margin of -728.57% compared to Bionano Genomics's net margin of -2.93%. Bionano Genomics's return on equity of -158.95% beat Azenta's return on equity of -7.49%.

    Company Gross Margin Earnings Per Share Invested Capital
    BNGO
    Bionano Genomics
    -139.08% -$0.52 $63.8M
    AZTA
    Azenta
    40.82% -$0.10 $1.8B
  • What do Analysts Say About BNGO or AZTA?

    Bionano Genomics has a consensus price target of --, signalling upside risk potential of 246.74%. On the other hand Azenta has an analysts' consensus of -- which suggests that it could grow by 13.2%. Given that Bionano Genomics has higher upside potential than Azenta, analysts believe Bionano Genomics is more attractive than Azenta.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNGO
    Bionano Genomics
    0 4 0
    AZTA
    Azenta
    0 0 0
  • Is BNGO or AZTA More Risky?

    Bionano Genomics has a beta of 2.220, which suggesting that the stock is 121.987% more volatile than S&P 500. In comparison Azenta has a beta of 1.475, suggesting its more volatile than the S&P 500 by 47.482%.

  • Which is a Better Dividend Stock BNGO or AZTA?

    Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BNGO or AZTA?

    Bionano Genomics quarterly revenues are $6.1M, which are smaller than Azenta quarterly revenues of $170.1M. Bionano Genomics's net income of -$44.2M is lower than Azenta's net income of -$5M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.40x versus 4.06x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNGO
    Bionano Genomics
    0.40x -- $6.1M -$44.2M
    AZTA
    Azenta
    4.06x -- $170.1M -$5M
  • Which has Higher Returns BNGO or BRKR?

    Bruker has a net margin of -728.57% compared to Bionano Genomics's net margin of 4.73%. Bionano Genomics's return on equity of -158.95% beat Bruker's return on equity of 19.61%.

    Company Gross Margin Earnings Per Share Invested Capital
    BNGO
    Bionano Genomics
    -139.08% -$0.52 $63.8M
    BRKR
    Bruker
    48.45% $0.27 $4.1B
  • What do Analysts Say About BNGO or BRKR?

    Bionano Genomics has a consensus price target of --, signalling upside risk potential of 246.74%. On the other hand Bruker has an analysts' consensus of $74.01 which suggests that it could grow by 26.25%. Given that Bionano Genomics has higher upside potential than Bruker, analysts believe Bionano Genomics is more attractive than Bruker.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNGO
    Bionano Genomics
    0 4 0
    BRKR
    Bruker
    7 5 0
  • Is BNGO or BRKR More Risky?

    Bionano Genomics has a beta of 2.220, which suggesting that the stock is 121.987% more volatile than S&P 500. In comparison Bruker has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.959%.

  • Which is a Better Dividend Stock BNGO or BRKR?

    Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.34% to investors and pays a quarterly dividend of $0.05 per share. Bionano Genomics pays -- of its earnings as a dividend. Bruker pays out 6.88% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BNGO or BRKR?

    Bionano Genomics quarterly revenues are $6.1M, which are smaller than Bruker quarterly revenues of $864.4M. Bionano Genomics's net income of -$44.2M is lower than Bruker's net income of $40.9M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Bruker's PE ratio is 28.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.40x versus 2.68x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNGO
    Bionano Genomics
    0.40x -- $6.1M -$44.2M
    BRKR
    Bruker
    2.68x 28.18x $864.4M $40.9M
  • Which has Higher Returns BNGO or HBIO?

    Harvard Bioscience has a net margin of -728.57% compared to Bionano Genomics's net margin of -21.86%. Bionano Genomics's return on equity of -158.95% beat Harvard Bioscience's return on equity of -20.42%.

    Company Gross Margin Earnings Per Share Invested Capital
    BNGO
    Bionano Genomics
    -139.08% -$0.52 $63.8M
    HBIO
    Harvard Bioscience
    58.1% -$0.11 $103.2M
  • What do Analysts Say About BNGO or HBIO?

    Bionano Genomics has a consensus price target of --, signalling upside risk potential of 246.74%. On the other hand Harvard Bioscience has an analysts' consensus of $6.25 which suggests that it could grow by 196.21%. Given that Bionano Genomics has higher upside potential than Harvard Bioscience, analysts believe Bionano Genomics is more attractive than Harvard Bioscience.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNGO
    Bionano Genomics
    0 4 0
    HBIO
    Harvard Bioscience
    2 0 0
  • Is BNGO or HBIO More Risky?

    Bionano Genomics has a beta of 2.220, which suggesting that the stock is 121.987% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.269, suggesting its more volatile than the S&P 500 by 26.945%.

  • Which is a Better Dividend Stock BNGO or HBIO?

    Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BNGO or HBIO?

    Bionano Genomics quarterly revenues are $6.1M, which are smaller than Harvard Bioscience quarterly revenues of $22M. Bionano Genomics's net income of -$44.2M is lower than Harvard Bioscience's net income of -$4.8M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.40x versus 0.93x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNGO
    Bionano Genomics
    0.40x -- $6.1M -$44.2M
    HBIO
    Harvard Bioscience
    0.93x -- $22M -$4.8M
  • Which has Higher Returns BNGO or RVTY?

    Revvity has a net margin of -728.57% compared to Bionano Genomics's net margin of 13.8%. Bionano Genomics's return on equity of -158.95% beat Revvity's return on equity of 3.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    BNGO
    Bionano Genomics
    -139.08% -$0.52 $63.8M
    RVTY
    Revvity
    56.26% $0.77 $11.1B
  • What do Analysts Say About BNGO or RVTY?

    Bionano Genomics has a consensus price target of --, signalling upside risk potential of 246.74%. On the other hand Revvity has an analysts' consensus of $138.68 which suggests that it could grow by 24.07%. Given that Bionano Genomics has higher upside potential than Revvity, analysts believe Bionano Genomics is more attractive than Revvity.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNGO
    Bionano Genomics
    0 4 0
    RVTY
    Revvity
    8 7 0
  • Is BNGO or RVTY More Risky?

    Bionano Genomics has a beta of 2.220, which suggesting that the stock is 121.987% more volatile than S&P 500. In comparison Revvity has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.677%.

  • Which is a Better Dividend Stock BNGO or RVTY?

    Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revvity offers a yield of 0.25% to investors and pays a quarterly dividend of $0.07 per share. Bionano Genomics pays -- of its earnings as a dividend. Revvity pays out 5.05% of its earnings as a dividend. Revvity's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BNGO or RVTY?

    Bionano Genomics quarterly revenues are $6.1M, which are smaller than Revvity quarterly revenues of $684M. Bionano Genomics's net income of -$44.2M is lower than Revvity's net income of $94.4M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Revvity's PE ratio is 54.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.40x versus 5.06x for Revvity. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNGO
    Bionano Genomics
    0.40x -- $6.1M -$44.2M
    RVTY
    Revvity
    5.06x 54.01x $684M $94.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Broadcom vs American Express: Which Is Best?
Broadcom vs American Express: Which Is Best?

Chip giant Broadcom Inc. (NASDAQ:AVGO) and card company American Express…

Why Is Adobe Stock Dropping?
Why Is Adobe Stock Dropping?

Why is Adobe stock dropping? A combination of underwhelming fiscal…

Why Is 3M Stock Going Up?
Why Is 3M Stock Going Up?

After a decade-long slump in new product introductions, the leading…

Stock Ideas

Buy
58
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 41x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 36x

Alerts

Buy
77
FTAI alert for Jan 2

FTAI Aviation [FTAI] is up 1.68% over the past day.

Buy
56
QMCO alert for Jan 2

Quantum [QMCO] is up 4.32% over the past day.

Buy
60
ARQQ alert for Jan 2

Arqit Quantum [ARQQ] is up 1.98% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock